Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CENTURY THERAPEUTICS, INC.

(IPSC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Century Therapeutics : SVB Leerink Initiates Coverage on Century Therapeutics With Outperform Rating, $33 Price Target

07/13/2021 | 08:44am EST


ę MT Newswires 2021
All news about CENTURY THERAPEUTICS, INC.
11/22Century Therapeutics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare..
AQ
11/19SVB Leerink Adjusts Century Therapeutics' Price Target to $32 from $33, Keeps Outperfor..
MT
11/18CENTURY THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/10Century Therapeutics Narrows Q3 Loss
MT
11/10Century Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business..
PU
11/10Earnings Flash (IPSC) CENTURY THERAPEUTICS Reports Q3 Loss $-0.48
MT
11/10Century Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business..
GL
11/10Century Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Thir..
CI
11/04Century Therapeutics to Present at the 63rd American Society of Hematology Annual Meeti..
AQ
10/13CENTURY THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news
Analyst Recommendations on CENTURY THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -93,3 M - -
Net cash 2021 343 M - -
P/E ratio 2021 -5,35x
Yield 2021 -
Capitalization 940 M 940 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 121
Free-Float 88,8%
Chart CENTURY THERAPEUTICS, INC.
Duration : Period :
Century Therapeutics, Inc. Technical Analysis Chart | IPSC | US15673T1007 | MarketScreener
Technical analysis trends CENTURY THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 17,20 $
Average target price 36,00 $
Spread / Average Target 109%
EPS Revisions
Managers and Directors
Osvaldo Flores Chief Executive Officer & Director
Douglas Carr Vice President-Finance & Operations
Joseph Jimenez Chairman
Hyam I. Levitsky President-Research & Development
Cynthia M. Butitta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CENTURY THERAPEUTICS, INC.0.00%940
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431